journal article·2021-11-24Open access

Library Screening to Identify Highly-Effective Autophagy Inhibitors for Improving Photothermal Cancer Therapy

Li Wang, Yitong Wang, Wei Zhao, Kaili Lin, Wei Li, Guodong Wang, Qiang Zhang

Nano Letters· Volume 21· Issue 22

Abstract

The small molecular inhibitor-associated downregulation of autophagy can remarkably enhance the efficiency of photothermal cancer therapy. To identify a more effective autophagy inhibitor, we screened a library of 20 compounds and found chloroquine, hydroxychloroquine, dauricine, and daurisoline were more efficient than the others to improve the photothermal killing of cancer cells. Interestingly, the four agents all disturb the autophagosome formation and fusion process, indicating it is a promising target to enhance cancer therapeutic efficiency. Among the four agents, daurisoline was identified to be the most efficient one. It reduced the viability of cancer cells treated by low-energy photothermal therapy from 86.27% to 32.92%. Finally, the combination treatment mediated by nanodrugs loaded with daurisoline and indocyanine green was more efficient than the individual modalities, resulting in complete inhibition of tumor growth. The study gives new inspiration to autophagy modulation-associated photothermal therapy and other therapeutic modalities for cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Autophagy in Disease and Therapy · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, P. R. China

Department of Oral & Cranio-Maxillofacial Surgery, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University; School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai 200011, P. R. China

Department of Stomatology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P. R. China

Funding

National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1039/D0CS00215A10.1039/D0CS00215A ↗
2. 10.1021/acs.nanolett.0c0014710.1021/acs.nanolett.0c00147 ↗
3. 10.1002/anie.20200300410.1002/anie.202003004 ↗
4. 10.1021/acsami.9b0462810.1021/acsami.9b04628 ↗
5. 10.7150/thno.1498810.7150/thno.14988 ↗
6. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
7. 10.1073/pnas.190692911610.1073/pnas.1906929116 ↗
8. 10.1039/C8TB00729B10.1039/C8TB00729B ↗
9. 10.1002/advs.20180150710.1002/advs.201801507 ↗
10. 10.1021/acsnano.9b0987110.1021/acsnano.9b09871 ↗
11. 10.1038/s41377-020-00388-310.1038/s41377-020-00388-3 ↗
12. 10.1016/j.ijbiomac.2020.06.20210.1016/j.ijbiomac.2020.06.202 ↗
13. 10.1021/acsami.0c0614410.1021/acsami.0c06144 ↗
14. 10.1080/15548627.2020.174659210.1080/15548627.2020.1746592 ↗
15. 10.1016/j.cell.2018.09.04810.1016/j.cell.2018.09.048 ↗
16. 10.1056/NEJMra202277410.1056/NEJMra2022774 ↗
17. 10.1242/jcs.11404110.1242/jcs.114041 ↗
18. 10.1038/s41467-019-13659-410.1038/s41467-019-13659-4 ↗
19. 10.1002/cncr.3133510.1002/cncr.31335 ↗
20. 10.1038/ncomms777910.1038/ncomms7779 ↗
21. 10.3390/cells909202210.3390/cells9092022 ↗
22. 10.1038/nrn396110.1038/nrn3961 ↗
23. 10.1021/nn500376w10.1021/nn500376w ↗
24. 10.1038/s41575-019-0136-810.1038/s41575-019-0136-8 ↗
25. 10.1038/s41467-021-23923-110.1038/s41467-021-23923-1 ↗
26. Chloroquine as an Anti-Autophagic Radiosensitzing Drug in Stage I-III Small Cell Lung Cancer, 2012, Identifier: NCT01575782, ClinicalTrials.gov, https://clinicaltrials.gov.
27. Chloroquine with Taxane Chemotherapy for Advanced or Metastatic Breast Cancer after Anthracycline Failure (CAT), 2011, Identifier: NCT01446016, ClinicalTrials.gov, https://clinicaltrials.gov.
28. 10.1039/C9CC03319J10.1039/C9CC03319J ↗
29. 10.1016/j.biomaterials.2017.06.03010.1016/j.biomaterials.2017.06.030 ↗
30. 10.1016/j.biomaterials.2019.02.02310.1016/j.biomaterials.2019.02.023 ↗
31. 10.1021/acsnano.5b0002110.1021/acsnano.5b00021 ↗
32. 10.1039/D0BM00142B10.1039/D0BM00142B ↗
33. 10.1166/jbn.2019.271410.1166/jbn.2019.2714 ↗
34. 10.1002/wnan.168010.1002/wnan.1680 ↗
35. 10.1038/s41388-021-01898-z10.1038/s41388-021-01898-z ↗
36. 10.1038/s41568-021-00344-210.1038/s41568-021-00344-2 ↗
37. 10.1080/15548627.2018.147431410.1080/15548627.2018.1474314 ↗
38. 10.1186/s12936-020-03541-w10.1186/s12936-020-03541-w ↗
39. Qian J. Q. · Acta Pharmacol. Sin. · 2002 · 23 · 1086
40. 10.18632/oncotarget.2076710.18632/oncotarget.20767 ↗
41. 10.4161/auto.8.2.1855410.4161/auto.8.2.18554 ↗
42. 10.1007/s00280-018-3669-610.1007/s00280-018-3669-6 ↗
43. 10.1038/nrd380210.1038/nrd3802 ↗
44. 10.1016/j.biomaterials.2019.11941910.1016/j.biomaterials.2019.119419 ↗
45. 10.1002/adfm.20210283210.1002/adfm.202102832 ↗
46. 10.3390/cancers1110159910.3390/cancers11101599 ↗
47. 10.1186/s13014-017-0795-y10.1186/s13014-017-0795-y ↗
48. 10.3390/cells802013810.3390/cells8020138 ↗
49. 10.1080/15548627.2018.146959010.1080/15548627.2018.1469590 ↗
50. 10.1039/C8PP00064F10.1039/C8PP00064F ↗
51. 10.1002/jps.1047010.1002/jps.10470 ↗
52. 10.1021/nn506238610.1021/nn5062386 ↗